Below for your information is a listing of the 2019 conferences and workshops. Mark your calendar for future IABS conferences, meetings and workshops and watch for future announcements regarding attendance and registration! If you are interested in a conference that was already held, check the IABS website (www.iabs.org) for summary information from the event.

Diagnostics in the Veterinary Field

May 15-17, 2019

Objectives of the meeting

Diagnostics are an essential tool to ensure the health of domestic and wild animals for both endemic and emerging diseases. They allow animal health professionals to understand and manage the general health status of domestic animals. They are also important tools to support public health initiatives in the case of zoonotic disease control. The meeting will provide an overview of existing systems and approaches / strategies for the use of diagnostics and to discuss the currently available diagnostics. The advantages / benefits and disadvantages / gaps of the current methods and methodologies will be identified and discussed. Proposals on how to increase the quality, efficacy, and utility of the existing strategies and methods and those under development will be made.

Scientific committee

Sandra Blome
Friedrich Löffler Institut
Attila Farsang
CEVA
Cyril Gay
USDA
Richard Hill
IABS
Carmen Jungbäck
IABS, Chair
Vaughn Kubiak
Zoetis
Serge Leterme
IDEXX
David Mackay
EMA
Paul Midtlyng
University of Oslo
Egbert Mundt
Boehringer-Ingelheim
Amir Noormohammadi
University of Melbourne
Sjaak de Wit
Deventer

Towards Rabies Elimination in Asia-Pacific – From Theory to Practice

September 25-26, 2019, Bangkok, Thailand

Objectives of the meeting

The meeting aims at snowballing efforts and achieving substantial progress in rabies control in the Asia-Pacific region of the world in the near future. As the key focus is placed on canine rabies the meeting will be an important contribution to the initiative of the United Against Rabies collaboration of the World Health Organization (WHO), World Organisation for Animal Health (OIE), Food and Agriculture Organization of the United Nations (FAO), and Global Alliance for Rabies Control (GARC) of ending human dog-mediated rabies by 2030. Recognized international and local experts will give insights into state-of-the art intersectoral One Health approaches, standards, available tools and guidelines developed by international organizations and institutions and best-practice examples from the region on how to prevent human rabies by eliminating rabies at its animal source. As such the meeting provides a platform for health and veterinary services, managers of national and local rabies eliminations programs, researchers and other people interested in advancing knowledge of rabies surveillance, prevention and control, to meet each other, to share their experience and also to discuss challenges to overcome. The meeting is considered to be a starting point for a continuous professional exchange on the way to a rabies free Asia-Pacific.

Scientific committee

Dr Charung Muangchana Director
National Veterinary Institute, Thailand
Dr Karoon Chanachai
Department of Livestock Development (DLD), Thailand
Dr Thomas Müller
Chair Friedrich-Loeffler-Institut, Germany
Dr Conrad Freuling
Friedrich-Loeffler-Institut, Germany
Dr Bernadette Abela-Ridder
World Health Organization
Dr Ivana Knezevic
World Health Organization
Dr Gregorio Torres
World Organization for Animal Health (OIE)
Dr Katinka de Balogh
Food and Agricultural Organization of the UN (FAO)
Dr Carmen Jungbäck
International Alliance for Biological Standardization (IABS)
Dr Gowri Yale
Mission Rabies
Prof. Louis Nel
Global Alliance for Rabies Control
Dr Ryan Wallace
Centres for Disease Control and Prevention, USA

Quality of challenge agent

An IABS-EU meeting

October 22, 2019 – Paul-Ehrlich Institute, Langen, Germany

Objectives of the meeting

One of the proposed tools for faster development of new vaccines is CHIM: Controlled Human Infectious Models. These models can be used for early PoC (Proof of Concept) and as a basis for clinical “Go/No Go” decisions, in particular if sporadic epidemiology impedes clinical development.
In these models researchers will use a challenge agent: a virus, bacterium or parasite. Frequently questions are raised on the quality of the agent. Should this agent be produced following GMP? What strain-related information is relevant? Should it be attentuated or resemble the wild type?

Scientific committee

Dr. Isabelle Bekeredjian-Ding
Paul-Ehrlich-Institut (PEI), Germany
Dr. Wim van Molle
Sciensano, Belgium
Dr. Heidi Meyer
Paul-Ehrlich-Institut (PEI), Germany
Dr. Christoph Conad
Paul-Ehrlich-Institut (PEI), Germany
Dr. Richard Rupp
University of Texas Medical Branch, U.S.A.
Dr. Nele Berthels
Federal Agency for Medicines and Health Products (FAMHP), Belgium
Dr. William Ripley Ballou
GlaxoSmithKline, U.S.A.

2nd Next Generation Sequencing for Adventitious Virus Detection in Human and Veterinary Biologics

An IABS-EU meeting

November 13-14, 2019 - University of Ghent, Belgium

Objectives of the meeting

This meeting will focus on the current scientific data and knowledge related to the use of next generation sequencing technologies for adventitious virus detection in biological products. Discussions will include ongoing efforts and future needs toward standardization and validation of the technical and bioinformatics steps involved in NGS for its applications in characterization and safety evaluation of biologics, including human and animal vaccines. The meeting will bring together representatives from industry, academia, technology providers, and international regulatory bodies for developing a scientific consensus regarding readiness of NGS for detection of adventitious viruses in biologics.

Scientific committee

Dr. Dieter Deforce, co-Chair
Ghent University
Dr. Sebastiaan Theuns, co-Chair
Ghent University
Dr. Arifa Khan
FDA
Dr. Sven Arnouts
Ghent University / PROVAXS
Dr. Johannes Blümel
Paul-Ehrlich-Institut (PEI)
Dr. William Egan
GlaxoSmithKline
Dr. Matthias Janssen
World Health Organization (WHO)
Dr. Carmen Jungbäck
International Alliance for Biological Standardization (IABS)
Dr. Ivana Knezevic
Word Health Organization (WHO)
Dr. David Mackay
formerlly EMA
Dr. Laurent Mallet
Sanofi Pasteur
Dr. Pieter Neels
International Alliance for Biological Standardization (IABS)
Dr. Gerald G. Schumann
Paul-Ehrlich-Institut (PEI)
Dr. Joseph Victoria
Boehringer-Ingelheim

2nd Setting Specifications for Biological Products: A Pathway to Harmonization

December 2-3, 2019 – USP Rockville, Thailand

Objectives of the meeting

This 2nd meeting will expand on considerations discussed in a September 2013 workshop and include participants from biotechnology medicinal products, vaccines, and gene & cell therapies. The goals of this workshop will be to explore the implications from lack of worldwide agreement on principles and practices in setting product specifications and discuss a pathway towards harmonization. Business and regulatory strategies for managing worldwide specifications will be reviewed and challenged. Data sources and statistical approaches for setting limits which reflect product quality will be discussed. The meeting will bring the right experts together to discuss the issues and through roundtables attempt to reach conclusions that will be valuable globally to public health.

Scientific committee

Shawn Novick
International Alliance for Biological Standardzation
Kris Barnthouse
Johnson and Johnson
Barry Cherney
Food and Drug Administration
Fiona Cornel
Health Canada
Melody Gossage
Eli Lilly and Company
Kristy Griffiths
Eli Lilly and Company
Brendan Hughes
Bristol-Myers Squibb
Robin Levis
Food and Drug Administration
Yunsong Li
Catalent
Anthony Lubinieki
International Alliance for Biological Standardzation
John McKnight
AstraZeneca
Ned.m.Mozier
Pfizer
Laura Pack
Seattle Genetics
Tim Schofield
International Alliance for Biological Standardzation
Meiyu Shen
Food and Drug Administration
Dean Smith
Health Canada
Vic Vinci
Catalent
Mats Welin
Medical Products Agency Sweden

Non-Animal testing for vaccines – A global congress

December 3-4, 2019 – Bangkok, Thailand

Objectives of the meeting

IABS and Vac2Vac are honoured to be organizing a Global Congress that will focus on replacement of in vivo testing of vaccines by in vitro methods with utilization of new and improved technologies. Progresses made with analytical tools and their applications have contributed to development of fast, precise and highly reliable in vitro tests that will allow batch to batch release of vaccines by consistency approach. Recent case studies on specific vaccines will be reviewed, and ongoing as well as future studies on other vaccines will be discussed. A particular emphasis will be placed on global coordination in areas of manufacturing and testing practices, and regulatory acceptance, with the goal of reducing time to market and increasing global access to vaccines. Participation from all of these areas of vaccine development, especially from LMICs and GAVI countries, is strongly encouraged. Bangkok has been selected as the site for this Congress because of its location amid countries with emerging vaccine producers and growing needs for vaccines.

We are honoured to have pledges of support from global foundations and partners from emerging economies.

Scientific committee

Dr.Coenraad Hendriksen, Chair Scientific Committee
Institute for Translational Vaccinology, The Netherlands
Dr. Supaporn Phumianmorn, co-Chair Scientific Committee
Department of Medical Sciences, Ministry of Public Health, Thailand
Dr. Gautam Sanyal
Vaccine Analytics, LLC, USA
Dr. Sunil Kumar Goel
Serum Institute India. India
Dr. Karl-Heinz Buchheit
European Directorate for the Quality of Medicines & HealthCare (EDQM), France
Dr. Laura Viviani
Humane Society International (HIS), Italy
Dr. Catrina Stirling
Zoetis, United Kingdom
Dr. Marlies Halder
EARL-ECVAM JRC, Italy
Dr. Yeowon Sohn
Seoul National University, Republic of Korea
Dr. Denis Lambrigts
GSK Biologicals, Belgium
Dr. Wassana Wijagkanalan
Government Affairs Manager, Thailand
Dr. Richard Hill
International Alliance for Biological Standardization (IABS), USA
Dr. Mario Landys
Cuerdo Finlay Institute, Cuba
Dr. Koji Ishii
National Institute of Infectious Diseases, Japan
Dr. Robin Levis
FDA, USA
Dr. Ai-Ping Hsu
Animal Health Research Institute, Taiwan
Dr. Thitawat Chanthaworn
National Institute of Animal Health, Thailand
Dr. Jim Webster
Ruakura Research Centre, New Zealand
Dr. Hilde Depraetere
European Vaccine Initiative (EVI), Germany
Dr. Sylvie Uhlrich
Sanofi-Pasteur Lyon, France
Dr. Carmen Jungbaeck
International Alliance for Biological Standardization (IABS), USA
Dr. Scott Craig
Therapeutic Goods Administrator, Australia
Dr. Bob Sitrin
Vaccine Development Global Program – APTH, USA

And next year, in 2020...

3rd Human Challenge Trials

More info coming soon...

February 6-7, 2020 – Oxford, United Kingdom

IABS 65th Anniversary: A global health conference

More info coming soon...

February 26-28, 2020 – Lyon, France

5th Cell & Gene Therapy

More info coming soon...

Q1 – Tokyo, Japan

Maintaining the quality of vaccines through the use of references standards

More info coming soon...

Q2 2020, Canada